Loading…
Madrigal Pharmaceuticals, Inc. is projected to rise to $657.73 by 2027, a +23% move from its current price of $536.70. MDGL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $525.14 | $536.74 | $548.59 | +0.01% |
| Jul 13 | $520.45 | $536.77 | $553.61 | +0.01% |
| Jul 14 | $516.89 | $536.81 | $557.50 | +0.02% |
| Jul 15 | $513.91 | $536.85 | $560.81 | +0.03% |
| Jul 16 | $511.30 | $536.88 | $563.75 | +0.03% |
| Jul 17 | $508.96 | $536.92 | $566.42 | +0.04% |
| Jul 18 | $506.81 | $536.96 | $568.90 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $506.81 | $536.96 | $568.90 | +0.05% |
| Week 2 | $495.07 | $537.22 | $582.96 | +0.10% |
| Week 3 | $486.29 | $537.48 | $594.05 | +0.14% |
| Week 4 | $479.05 | $537.74 | $603.61 | +0.19% |
| Week 5 | $472.79 | $538.00 | $612.19 | +0.24% |
| Week 6 | $467.22 | $538.26 | $620.09 | +0.29% |
| Week 7 | $462.18 | $538.52 | $627.46 | +0.34% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania. It operates in the Healthcare sector and works to develop treatments for metabolic liver disease.
MDGL trades as Madrigal Pharmaceuticals, Inc. in the Healthcare sector. The current price is $565.40 per share, and the company has a market cap of $13.04B with a rank of 772.
Forecasts indicate upside potential over the long horizon, with the 2026 average price at $565.40, rising to $1,272.77 by 2030 and $7,606.53 by 2050. This progression suggests meaningful long-run upside despite the near-term price being near the current level.
A major floor 24.4% below — a decisive break under it would weaken the trend.
The nearest floor, 15.6% below — buyers have tended to step in here.
The nearest ceiling, 5.3% above — a clean break opens room to run.
A major ceiling 17.5% above — clearing it would confirm fresh momentum.
Key MDGL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MDGL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $547.39 | Sell | $544.68 | Sell |
| MA 10 | $535.63 | Buy | $536.67 | Buy |
| MA 20 | $518.39 | Buy | $524.91 | Buy |
| MA 50 | $511.48 | Buy | $513.21 | Buy |
| MA 100 | $495.63 | Buy | $504.65 | Buy |
| MA 200 | $499.95 | Buy | $480.48 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.75 | Neutral |
| Stoch RSI (14) | 16.70 | Buy |
| CCI (20) | 67.01 | Neutral |
| Williams %R (14) | -51.58 | Info |
| MACD (12,26,9) | 4.14 | Buy |
| ROC (12) | 4.53 | Buy |
| Bollinger %B (20,2) | 0.70 | Neutral |
| Stochastic %K (14) | 48.42 | Neutral |
| TRIX (15) | 0.23 | Buy |
| Awesome (5,34) | 39.11 | Buy |
| Ultimate (7,14,28) | 53.94 | Neutral |
| Momentum (10) | 22.91 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 561.45 | Sell |
| ADX (14) | 16.41 | Neutral |
| ATR (14) | 10.88 | Info |
The 30-day technical picture is bullish. RSI14 is 70, signaling strong near-term momentum.
The stock trades above the 50-day and 200-day simple moving averages, with SMA50 at $510.28 and SMA200 at $498.86. Near-term support is $452.86 and resistance is $565.40. The 30-day price range runs from $492.00 to $649.75, indicating a potential for upside within the month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $425.85 | $536.70 | $699.76 | 0% | Neutral | |
| $533.33 | $657.73 | $851.86 | +23% | Bullish | |
| $612.25 | $771.71 | $1,030.36 | +44% | Bullish | |
| $767.29 | $984.69 | $1,346.58 | +83% | Bullish | |
| $879.15 | $1,146.23 | $1,599.51 | +114% | Bullish | |
| $963.39 | $1,274.21 | $1,809.90 | +137% | Bullish | |
| $1,022.50 | $1,370.49 | $1,977.96 | +155% | Bullish | |
| $1,063.02 | $1,442.62 | $2,112.45 | +169% | Bullish | |
| $1,274.91 | $1,750.66 | $2,598.00 | +226% | Bullish | |
| $1,505.30 | $2,090.34 | $3,140.90 | +289% | Bullish | |
| $2,128.35 | $3,108.28 | $4,921.84 | +479% | Bullish | |
| $4,024.31 | $6,396.82 | $10,942.44 | +10.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $425.85 | $536.70 | $647.52 | +0.00% |
| August 2026 | $463.42 | $544.13 | $653.98 | +1.38% |
| September 2026 | $457.43 | $540.08 | $654.93 | -0.74% |
| October 2026 | $468.48 | $555.76 | $679.05 | +2.90% |
| November 2026 | $478.29 | $569.70 | $700.48 | +2.51% |
| December 2026 | $473.24 | $565.80 | $699.76 | -0.68% |
Click any year to see its month-by-month MDGL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MDGL is projected to trade between $425.85 and $699.76, averaging $536.70 — a potential gain of 0% from today's $536.70. A consolidation phase looks the most probable path here.
Madrigal Pharmaceuticals, Inc.'s 2027 outlook centres on $657.73, within a $533.33 to $851.86 range. That is up +23% on the projected 2026 average. That marks a +23% change versus current levels. Momentum favours further upside here.
By 2028, MDGL could reach as high as $1,030.36, with a base case around $771.71 and support toward $612.25 — roughly +44% from $536.70. Buyers look set to stay in control over this stretch.
Expect MDGL to range from $767.29 to $1,346.58 through 2029. The $984.69 average target implies a +83% move from current prices. That is up +28% on the projected 2028 average. Momentum favours further upside here.
The MDGL price prediction for 2030 points to an average of $1,146.23 (low $879.15, high $1,599.51) — a potential gain of +114% on today's $536.70. Buyers look set to stay in control over this stretch.
In 2031, MDGL is projected to trade between $963.39 and $1,809.90, averaging $1,274.21 — a potential gain of +137% from today's $536.70. That is up +11% on the projected 2030 average. Momentum favours further upside here.
Madrigal Pharmaceuticals, Inc.'s 2032 outlook centres on $1,370.49, within a $1,022.50 to $1,977.96 range. That is up +8% on the projected 2031 average. That marks a +155% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, MDGL could reach as high as $2,112.45, with a base case around $1,442.62 and support toward $1,063.02 — roughly +169% from $536.70. Momentum favours further upside here.
Expect MDGL to range from $1,274.91 to $2,598.00 through 2034. The $1,750.66 average target implies a +226% move from current prices. That is up +21% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The MDGL price prediction for 2035 points to an average of $2,090.34 (low $1,505.30, high $3,140.90) — a potential gain of +289% on today's $536.70. Momentum favours further upside here.
In 2040, MDGL is projected to trade between $2,128.35 and $4,921.84, averaging $3,108.28 — a potential gain of +479% from today's $536.70. That is up +49% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Madrigal Pharmaceuticals, Inc.'s 2050 outlook centres on $6,396.82, within a $4,024.31 to $10,942.44 range. That is up +106% on the projected 2040 average. That marks a +10.9x change versus current levels. Momentum favours further upside here.
Investing $1,000 in MDGL today (≈ 1.863238 MDGL) could be worth
$11,918.81
+$10,918.81 (+1092%) by 2050 · US Dollar
Based on the average projected MDGL price of $6,396.82 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MDGLwould be worth at today's price.
$1,000 invested in MDGL on Jul 10, 2025 (≈ 3.178235 MDGL) would be worth
$1,705.76
+$705.76 (+70.6%) today · 1.71× · US Dollar
Based on a MDGL entry price of $314.64 vs. today's $536.7.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $528.1 | $1,016.28 | +1.6% |
| 1 month ago | $471.32 | $1,138.72 | +13.9% |
| 3 months ago | $519.61 | $1,032.89 | +3.3% |
| 6 months ago | $510.53 | $1,051.26 | +5.1% |
| 1 year ago | $314.64 | $1,705.76 | +70.6% |
| All time (5.0y) ago | $105.02 | $5,110.46 | +411.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MDGL forecast.
Our base-case forecast reaches $1,100.00 around 2030.
Implied market cap at $1,100.00: $25.36B
The multi-year forecast shows bullish sentiment across the horizon, with several years featuring rising averages. In 2027 the average is $708.43 (ROI 25.3%), and in 2028 the average is $842.49 (ROI 49%). In 2029 the average is $1,083.66 (ROI 91.7%), and by 2030 the average is $1,272.77 (ROI 125.1%).
Further out, 2035 averages rise to $2,401.10 (ROI 324.7%), 2040 to $3,649.26 (ROI 545.4%), and 2050 to $7,606.53 (ROI 1245.3%). These are estimates and not guarantees; actual results may differ and depend on a range of market and clinical factors.
Tap a question to reveal the answer.
2030 avg price is $1,272.77 with a min of $980.58 and a max of $1,766.09; ROI 125.1%; sentiment bullish.
Yes. The forecast shows bullish sentiment across years, with 2027 avg $708.43 (ROI 25.3%), 2030 avg $1,272.77 (ROI 125.1%), and 2050 avg $7,606.53 (ROI 1245.3%).
Yes. The 2029 average is $1,083.66 and the 2029 range min $847.67, max $1,474.45, indicating the potential to exceed $1,000.
RSI14 is 70 with sentiment bullish. SMA50 is $510.28, SMA200 is $498.86. Support is $452.86 and resistance is $565.40. The 30-day range is $492.00 to $649.75.
Current price is $565.40; market cap is $13.04B; rank 772.
Madrigal Pharmaceuticals, Inc. Community Discussion
0Share your Madrigal Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.